{"id":"W2020299781","doi":"10.1007/s00280-011-1671-3","title":"PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Aldose Reductase and Taurine","field":"Biochemistry, Genetics and Molecular Biology","cited_by":36,"is_retracted":false,"has_abstract":false,"ca_institutions":"Impact","funders":"","keywords":"Sorafenib; Hepatocellular carcinoma; Medicine; Neutropenia; Internal medicine; Gastroenterology; Discontinuation; Liver function; Cohort; Pharmacokinetics; Pharmacology; Oncology; Toxicity","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000394564,0.000164549,0.0001723551,0.00003611244,0.00003876729,0.000003292099,0.00009534723,0.000101047,0.000247193],"category_scores_gemma":[9.582012e-7,0.0001411837,0.00002655586,0.00007325562,0.0001059574,0.000006448364,0.00002991798,0.00009186228,0.000001601384],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000250281,"about_ca_system_score_gemma":0.00008931247,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004818095,"about_ca_topic_score_gemma":0.00001131823,"domain_scores_codex":[0.9992194,0.00003140622,0.0001272844,0.0003210127,0.00005253066,0.0002483995],"domain_scores_gemma":[0.9996944,0.000003211068,0.00006023863,0.0001210974,0.0000429832,0.00007805042],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.004454075,0.0002975085,0.6890684,0.00005732453,0.0001783142,0.00002128276,0.0006510415,0.000010488,0.2946434,0.00002179282,0.001055152,0.009541161],"study_design_scores_gemma":[0.01008895,0.0007322098,0.06831817,0.000009173106,0.00003244222,0.000003739357,0.00003087116,0.00004337546,0.900349,0.00002679204,0.02007148,0.0002938223],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964617,0.002573979,0.00003327985,0.00006941525,0.000162549,0.0003278035,0.0000182728,0.000008287645,0.0003447084],"genre_scores_gemma":[0.997036,0.001284312,0.0001390885,0.001063206,0.0001644188,0.0000904471,0.00005274888,0.00002659661,0.0001431738],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6207502,"threshold_uncertainty_score":0.5757305,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01115251387590443,"score_gpt":0.2449526521845511,"score_spread":0.2338001383086467,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}